Amgen's Perlmutter joins Immune Design board
This article was originally published in Scrip
Executive Summary
Immune Design Corp has appointed Dr Roger Perlmutter to its board of directors. Until earlier this year, Dr Perlmutter served as executive vice-president of research and development at Amgen.
You may also be interested in...
Merck Strengthening Vaccine Capabilities By Acquiring Troubled Immune Design
Recently battered by clinical setbacks, Immune Design has a co-development partnership with Merck around Keytruda and Merck’s Perlmutter is a former board member. Merck would pay roughly $300m to acquire the company and its immune system-boosting technologies.
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.